US expert panel recommends resumption of J&J Covid-19 vaccinations
Issued on: Modified:
An expert panel in the United States has recommended the resumption of Johnson & Johnson's Covid-19 vaccination, after a pause prompted by blood clot concerns.
US health authorities 14 April proposed a halt on the vaccine following instances of severe blood clots out of millions of Americans who received the coronavirus vaccine.
"The Janssen Covid-19 vaccine is recommended for persons 18 years of age and older in the US population under the FDA, emergency use authorization," the experts convened by the CDC said.
According to data presented Friday, of 3.9 million women who got the Johnson & Johnson shot, 15 developed serious blood clots and three died.
The majority of the confirmed cases, 13 of the 15, was less than 50 years old. There were no reported cases among men.
Europe's medicines regulator said Tuesday that blood clots should be listed as a "very rare" side effect of Johnson & Johnson's coronavirus vaccine.
The regulator said its safety committee "concluded that a warning about unusual blood clots with low blood platelets should be added to the product information" for the J&J shot.
Johnson & Johnson has negotiated a warning label for its Covid-19 vaccine to make health care providers aware of a potentially increased risk of rare but severe blood clots and low platelet counts https://t.co/TMfp0KQtjn— POLITICO (@politico) April 23, 2021
Daily newsletterReceive essential international news every morningSubscribe